Hypertension remains the most prevalent chronic disease in the world, and its adequate treatment results in predictable reductions in cardiovascular morbidity and mortality. However, most hypertensive subjects do not achieve goal blood pressure despite availability of multiple antihypertensive agents with various pharmacological mechanisms of action and relatively few side effects. We review the reasons for low hypertension control rates, including factors that affect patients' adherence to therapy, number of agents required to achieve goal blood pressure, pathophysiology-based selection of therapy and diagnosis of resistant hypertension. Within this framework, we discuss the possible impact of a single-pill, triple-therapy combination with an antagonist of the renin-angiotensin system, a calcium-channel blocker and a diuretic. We focus on possible differential diagnostic implications in terms of refractoriness to treatment, and therapeutic implications in terms of successful blood pressure control. We conclude that a single-pill, triple-therapy combination may improve control of hypertension by enhancing compliance, by achieving blood pressure goal rapidly and by reducing physician inertia in prescribing adequate antihypertensive therapy. We also suggest that such a combination may lead to improved accuracy in diagnosing resistant hypertension in general practice, avoiding unnecessary further workup and referrals to hypertension specialists.
Introduction
Six decades of epidemiological and clinical research have provided unequivocal evidence for the role of hypertension as a cardiovascular and renal risk factor and for the benefit of antihypertensive therapy. Concomitantly, pharmaceutical research has resulted in the development of a large armamentarium of antihypertensive drugs with a variety of mechanisms of action that address the diverse pathophysiologies of essential hypertension. Despite this extraordinary progress, control rates of hypertension, although somewhat improved, remain dismal, even in developed, wealthy societies. The sobering disparity between the science and its clinical application has resulted in the understanding that future developments in the field must address strategies to bridge the gap between them.
Epidemiology has established hypertension as a risk factor for cardiovascular disease in studies of large and diverse populations, and has quantified such risk with extreme accuracy. A meta-analysis containing data on 12.7 million patient-years of follow up documented that minor differences in blood pressure (2 mmHg) have a major impact on ischemic heart disease or stroke mortality (7% and 10% decreases, respectively) [Lewington et al. 2002] .
The demonstration, in 1959, by Kincaid-Smith that blood pressure reduction dramatically increased survival in subjects with malignant hypertension [Harington et al. 1959] began the journey of investigation that documented analogous results in subjects with progressively lower levels of diastolic blood pressure [VA and NIH-sponsored trials: Neaton et al. 1993; Hypertension Detection and Follow-up Program Cooperative Group, 1982 ; Veterans Administration Cooperative Study Group on Antihypertensive Agents 1970 Agents , 1967 in those with isolated systolic hypertension (SHEP [Cooperative Research Group 1991] and Syst-Eur [Tuomilehto et al. 1999] ) and most recently, in the 'superelderly' (HYVET [Beckett et al. 2008] ). The most striking observation of these studies is that pharmacological reduction of blood pressure removes the risks of stroke and ischemic heart disease by a magnitude almost equal to that predicted by epidemiology, a feature that is perhaps unique to the treatment of hypertension. This emphasizes the need to translate scientific knowledge to the health of the population.
Control rates of blood pressure among all hypertensive subjects in the US are 33% [Ong et al. 2007] , worse in Europe [Chamontin et al. 2001] , and even worse in developing countries [Gu et al. 2002] . They are calculated according to target blood pressure goals derived from clinical trials (5140/90 mmHg for uncomplicated hypertensire subjects and 5130/80 mmHg in those with diabetes, renal disease and high cardiovascular risk in some guidelines) despite the fact that the blood pressure/risk relationship increases linearly from a level of 115/75 mmHg. The latter has led to the widely accepted definition of 'normal' blood pressure as 5120/ 80 mmHg. Although there is no definitive evidence for a benefit of blood pressure reduction from 140/90 to 120/80, there has been recent speculation about exploiting this range of 'pre-hypertension' values to improve control rates with a more aggressive approach to treatment. Specifically, it has been stated: 'Healthcare professionals should be urged to keep in mind that it is not sufficient to bring patients close to goal. Rather, they need to treat hypertension to or below goal levels' ].
Reasons for low hypertension control rates are multiple (Table 1) , and much has been written about methods to improve them. This review will focus on the rationale for combining three antihypertensive agents in a single pill, a conceivable pharmaceutical development in the near future, to improve control rates of hypertension.
Factors impairing control of blood pressure in general practice
The physician's power to influence socioeconomic conditions that impair control rates of hypertension (poverty, insurance, education, health care delivery system pressures for productivity) is limited to his or her role as a citizen. In contrast, there are methodological (proper blood pressure measurement technique), diagnostic (pseudohypertension, white coat syndrome, secondary forms of hypertension), educational (lifestyle modification, salt intake) and therapeutic (drug interactions, side effects) issues that affect control rates and are within the clinical realm.
Perhaps the two most powerful elements with which physicians can affect blood pressure control rates are self-management of therapeutic inertia and appropriate selection of drug therapy. Therapeutic inertia is defined as failure to initiate or increase therapy when indicated, despite clearly established guidelines and documented beneficial outcomes [Elliott, 2008; Phillips et al. 2001 ]. This phenomenon is independent of issues of patient adherence or access to care, and probably results from relying on 'soft' reasons not to change therapy or lack of practice organization to promote such changes. Productivity pressures that shorten the patient-physician interaction and the multiple, sometimes conflicting, guidelines regarding therapy compound the issue.
However, it has been argued that correcting inertia may not suffice to obtain control of blood pressure in all patients. A recent study employing a modification of survival (Kaplan-Meier) analysis [Bailey et al. 2008 ] demonstrated that the diminished efficacy of antihypertensive therapy in the elderly, in whom therapeutic inertia by physicians is also increased, would not allow for achieving control rates in excess of 65%, even if the elderly were treated as aggressively as the youngest studied group. If this observation were interpreted to mean that current blood pressure goals for the elderly are unrealistic, it would discourage practitioner efforts. In contrast, we believe it should stimulate creativity to modify our approaches to therapy, either by developing newer therapeutic agents, or by changing the mode of administration of currently available ones.
Side-effects, convenience, early success and adherence to therapy Side effects of antihypertensive medications are a major deterrent to patient compliance [Elliott, 2008] . The progressive abandonment of old antiadrenergic agents with multiple symptomatic side effects, owing to the development of new therapeutic agents with a better profile, has been a major advancement in hypertension therapy. Newer agents, particularly the angiotensin-receptor blockers (ARBs) developed a decade ago, epitomize this result [Payne and Esmonde-White, 2000] .
Overall rates of adverse events reported in clinical trials of ARBs are comparable to those of placebo, allowing the physician to encourage patients to use them consistently, with an assurance that it is extremely unlikely that they will develop undesired symptoms.
Analogously, the detrimental impact of inconvenience on compliance [Elliott, 2008] led industry to focus pharmaceutical research on agents with long duration of action that can be taken once daily. Many once-a-day drugs, belonging to different therapeutic families, have displaced older, shorter-acting drugs (multiple daily doses) from the market.
The issue of combining therapies in a single tablet, to increase convenience, adherence and efficacy, has a long history, beginning with products containing rauwolfia derivatives, hydralazine and diuretics, that became available more than 50 years ago. Although in the past there were those who feared relinquishing flexibility in dosing the individual component drugs, acceptance of combining drugs in a single tablet has increased to the point that discussions are being held on the possible value of a 'polypill' to treat a multiplicity of risk factors or established cardiovascular disease [Combination Pharmacotherapy and Public Health Research Working Group, 2005; Wald and Law, 2003] . Although such polypill (aspirin, statins, beta-blockers, ACEinhibitors, etc.) has not materialized yet, and would have the problem of lack of individual drug titration, there is at least one limited example of this approach in the US market, a tablet containing the antihypertensive agent amlodipine and the lipid therapy agent atorvastatin. In the hypertension field, combination therapy with newer antihypertensive agents produces greater blood pressure reduction at lower doses of the individual agents, has the potential to cause fewer adverse events [Chobanian et al. 2003 ], may cost less (only 1 copy [Elliott, 2008] ), and is well tolerated [Sica, 2002] . Moreover, there is some indication that combining two agents in one tablet may lead to better compliance than prescribing them separately [Gerbino and Shoheiber, 2007; Taylor and Shoheiber, 2003 ].
JNC7 was the first guideline advocating first-line combination therapy for those subjects requiring 20/10 mmHg blood pressure reduction (stage 2 hypertension) [Chobanian et al. 2003 ].
Although there were multiple reasons for this recommendation, recognition of the importance of getting to goal as rapidly as possible was one of them [Staessen et al. 2004; Weber et al. 2004] . Actually, JNC7 explicitly mentioned the importance of establishing trust in the physicianpatient relationship to improve adherence [Chobanian et al. 2003 ]. Consistent with these recommendations, the FDA has more recently approved the combinations valsartan/amlodipine, valsartan/hydrochlorothiazide and irbesartan/ hydrochlorothiazide as first-line therapies for hypertension.
Rapid achievement of goal blood pressure, rather than a protracted vicious cycle of ever increasing monotherapy dosages with the potential for more adverse events, has the obvious advantage of deterring patient frustration; that is, to increase trust in the therapeutic relationship, hence, adherence to treatment [Gradman and Acevedo, 2002] . European guidelines followed and expanded on JNC7, advocating combination therapy for stage 2 hypertension and for those with elevated cardiovascular risk [Mancia et al. 2007 ].
Number of different antihypertensive drugs required to reach blood pressure goals in clinical trials Concomitant with our progressive understanding of the epidemiology of hypertension and the beneficial effects of treatment, there has been a progressive lowering of the blood pressure values considered as the optimal treatment target. Therefore, in research exploring outcomes of treatment of hypertension, regardless of the specific question posed in a particular clinical trial, there have been progressive attempts at reaching increasingly tighter blood pressure control levels in the participants.
Large trials such as ALLHAT, LIFE and ASCOT, focusing on cardiovascular morbidity and mortality, led to the recognition that most patients with hypertension will require at least two medications to control blood pressure [ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002; Dahlof et al. 2005 Dahlof et al. , 2002 . Nearly 80% of patients in the ASCOT-BPLA were taking two or more medications at study end. In studies involving patients at high risk [Hansson et al. 1998 ], diabetics [Brenner et al. 2001; Lewis et al. 2001; UK Prospective Diabetes Study Group, 1998 ], or exploring renal outcomes [Wright et al. 2002; Brenner et al. 2001; Lewis et al. 2001; Klahr et al. 1994] , particularly if blood pressure goals were lower than 140/90 mmHg, the average number of agents required to achieve blood pressure control in the more aggressively-treated group was 3.2 [Blood Pressure Lowering Treatment Trialists' Collaboration, 2003] .
The recognition of the need for several drugs to achieve control, plus the issues of convenience and side effects affecting adherence mentioned above, led to the development of single-pill combination therapies involving almost all newer classes of antihypertensive agents. Hence, in the US market there are combinations of thiazide diuretics with beta-blockers, ACEinhibitors or ARBs, as well as combinations of nondihydropyridine calcium channel blockers with ACE-inhibitors, dihydropyridine calcium channel blockers with ACE-inhibitors and the most-recently approved dihydropyridine calcium channel blockers with ARBs. An example of the latter, the combination amlodipine/valsartan, now has FDA approval for use as first line therapy of hypertension.
Triple-therapy combinations and resistant hypertension
Resistant hypertension is currently defined as the failure to reach risk factor-tailored goal blood pressure, despite treatment with optimal doses of three pharmacological agents of different families, one of which is a diuretic. It is more common in the elderly, diabetics, obese and those with hypertensive heart disease or chronic kidney disease [Calhoun et al. 2008 ]. Inclusion of a diuretic in this definition is based on the recognition that these agents are effective and inexpensive, potentiate the effect of other antihypertensive agents, and contribute a specific effect to individuals with salt-sensitivity of blood pressure (a little more than half of Caucasian, and at least two-thirds of African American [Calhoun et al. 2008] and Hispanic hypertensive subjects [Laffer and Elijovich, 2002] ). The mechanism of salt-sensitivity of blood pressure is not fully understood, although there is strong evidence for a role of deficient natriuretic derivatives of cytochrome p450 metabolism of arachidonic acid in both rodents [Ma et al. 1994 ] and humans [Laffer et al. 2008 [Laffer et al. , 2003 . Despite lack of a clear mechanism, salt-sensitivity of blood pressure confers cardiovascular risk independent of blood pressure [Weinberger et al. 2001] , emphasizing the importance of treating the potential contribution of salt to blood pressure elevation in all patients, which is not consistently done in general practice [Amar, 2007] .
Establishing an accurate diagnosis of resistant hypertension is of the utmost importance, because if confirmed, it will lead to a series of cumbersome, costly and even risky interventions. For example, every resistant hypertensive subject requires exclusion of a concealed undiagnosed cause of secondary hypertension, despite the lack of clinical clues to suspect it. This requires complex and expensive biochemical and radiological testing. In the absence of a secondary cause for hypertension, hydrochlorothiazide may be switched to the more potent diuretic chlorthalidone, or a therapeutic trial of spironolactone may be attempted, the latter particularly in obese subjects [Gaddam et al. 2008 ], on the basis of possible stimulation of inappropriate adrenal release of aldosterone by adipocyte secretagogues [Goodfriend et al. 2002] . Although effective, these strategies are not devoid of risk, particularly in populations that are likely to have both resistant hypertension and risk for thiazideinduced hyponatremia (elderly) or for hyperkalemia (subjects with diabetes, who commonly have RTA IV, and those with chronic renal insufficiency).
Given the issues of convenience and adherence mentioned above, there is an obvious role for single-pill triple-therapy in establishing an accurate diagnosis of resistant hypertension. Its use could be advocated in patients with uncontrolled hypertension who are: (a) taking two separate drugs, in which triple therapy would be achieved while concomitantly reducing the number of pills rather than by adding a third one (i.e. potential for increased adherence), (b) taking a two-drug combination, in which triple therapy would be the logical progression for an already instituted combination-therapy strategy, and (c) taking three separate drugs, in whom refractoriness may be due to issues of adherence, not of therapeutic efficacy. Improvement in compliance with single-pill, double-therapy [Gerbino and Shoheiber, 2007; Taylor and Shoheiber, 2003] , makes it likely that single-pill triple therapy may have a role in establishing a differential diagnosis between less than optimal adherence to therapy (with separate agents) and authentically refractory hypertension, although there is no published study addressing this possibility.
The drugs to be combined and the pathophysiology of essential hypertension It is pretty well accepted that blood pressure elevation is a phenotypic manifestation common to many distinct pathophysiological mechanisms; that is, the term essential hypertension most likely includes different diseases that have not been sorted out owing to our present state of knowledge. Many vasoactive and regulatory mechanisms have been shown to influence blood pressure. However, seminal experiments in the 1970s demonstrated the major participation of an interaction between activation of the renin-angiotensin system and the state of sodium balance in the elevation of blood pressure. Studies were conducted in experimental models of renovascular hypertension, Goldblatt two-kidney, one clip (2K1C) and Goldblatt one-kidney, one clip (1K1C), but their findings are applicable to essential hypertension. In the 2K1C model, activation of renin secretion by the clipped kidney leads to sustained renin-dependent hypertension; pressure-natriuresis by the contralateral, nonclipped kidney maintains a normal (or even contracted) effective plasma volume, allowing for continuous oversecretion of renin by the clipped one [Gavras et al. 1975] . In contrast, renindependence of hypertension in the 1K1C model is short-lived, because natriuresis is impaired by the absence of the contralateral kidney. This is followed by volume expansion, and suppression of renin release by the clipped kidney [Gavras et al. 1973] . Restoration of normal volume in 1K1C by diuretics restores blood pressure dependence on renin, unequivocally demonstrating the interdependence of these two mechanisms.
A group of hypertension experts at Cornell University has advocated measurement of plasma renin activity (PRA) to guide selection of initial therapy in essential hypertension, assuming that renin-dependent and renin-independent forms of hypertension can be identified in humans and that in doing so, the effectiveness of initial monotherapies targeted to these two forms of hypertension would be increased [Blumenfeld and Laragh, 1998 ]. Aside from issues of methodology (differences between PRA assays) and cost (a relatively expensive test for a prevalent disease affecting millions of people), this practice was never widely accepted because of lack of demonstration of its basic premise in a large clinical trial. Use of demographic surrogates of PRA (such as age and race/ethnicity) for selection of therapy would solve the issue of the cost of the assay. However, these surrogates misidentify the underlying mechanism in a significant percentage of patients and have also been criticized on the basis of a different rationale: blockers of the renin-angiotensin system provide benefits beyond blood pressure reduction (e.g. decreased target organ damage [Okin et al. 2003] ). Therefore, underuse of these agents in patients with low PRA, either measured or predicted by demographics (e.g., the elderly or African-American hypertensives) may inappropriately withhold these agents from populations at high risk for cardiovascular damage. Furthermore, there is evidence that the blood pressure response to blockers of the reninangiotensin system in patients with low circulating PRA may simply be an issue of dose; similar blood pressure responses to those in their counterparts with higher PRA can be reached at doses higher than those listed as maximal by the FDA [Weir et al. 1995] .
Nonetheless, recognition of the mechanisms above has a reflection in the current practice of medicine and in drug development trends. It is not uncommon that practitioners, facing the failure of a drug addressing one of these two major pathophysiologic mechanisms, will add a second drug that addresses the other. For example, there is no question that the activation of renin-release by a diuretic will potentiate the antihypertensive effect of any blocker of the renin-angiotensin system (there is ample proof for ACE-inhibitors, ARBs and the direct renin inhibitor aliskiren). Furthermore, there is evidence that the approach of targeting two pathophysiological mechanisms may prevent untoward effects of one family of agents by the other (e.g. dampened calcium-channel blocker activation of renin [Jamerson and Basile, 2008] , or diminished untoward metabolic effects of diuretics [Motwani, 2002] by renin-angiotensin system blockers). Also, these combinations reduce blood pressure promptly [Bakris and Weir, 2003] , increase adherence [Taylor and Shoheiber, 2003] , increase the proportion of patients reaching goal [Philipp et al. 2007] , and most importantly, improve outcomes [Dahlof et al. 2005] . Actually, the recently published ACCOMPLISH trial started to address the issue of the impact of different combinations of antihypertensive agents on the outcomes of hypertensive subjects at high risk, a clinical research trend that will most certainly grow in the near future .
The practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available twodrug combinations have an agent that addresses renin secretion (beta-blocker, ACE-inhibitor, ARB or aliskiren) and another one that is statistically more effective in renin-independent hypertension (diuretic, dihydropyridine or nondihydropyridine calcium channel blocker).
Addition of hydrochlorothiazide to the combination of an antagonist of the reninangiotensin system (ACE-inhibitor or ARB) and a calcium channel blocker; that is, single-pill triple therapy, would constitute a logical approach. Whereas renin-dependent and reninindependent forms of vasoconstriction would be addressed by the two latter agents, addition of hydrochlorothiazide would make the triple-therapy fulfil the additional requisite for management of resistant hypertension. In addition to covering major pathophysiological mechanisms and providing a treatment for resistant hypertension, some agents that could be used in this type of combination have outcomes data to support their use in diverse patient populations. The effectiveness and noninferiority of valsartan in the treatment of high-risk hypertension was documented in the large VALUE trial , while its beneficial effects in congestive heart failure and ischemic heart disease were documented in the ValHeFT [Cohn et al. 2001] and VALIANT [Pfeffer et al. 2003 ] trials, respectively. Amlodipine does not benefit outcomes in heart failure when added to blockers of the renin-angiotensin system and diuretics. However, it is known to be devoid of the detrimental effects that were anticipated because of its vasodilator effect and possible reflex sympathetic activation in heart failure [Packer et al. 1996] . Also, the increase in glomerular filtration rate produced by amlodipine in clinical trials of hypertensive subjects with renal disease [Wright et al. 2002] , once combined with the efferent arteriolar dilatation induced by blockade of the renin-angiotensin system (protection from glomerular hypertension), could be advantageous, rather than detrimental, for long-term preservation of renal function in patients with chronic renal failure.
Conclusions and perspectives
This manuscript reviews the evidence by which triple-therapy combination for hypertension, with a blocker of the renin-angiotensin system, a dihydropyridine calcium-channel blocker that addresses non-renin-dependent vasoconstriction, and a thiazide diuretic may contribute to improved control rates of blood pressure. Issues supporting this suggestion include: (a) benign side-effect profile of angiotensin-receptor blockers and its potential to enhance adherence, (b) current established guidelines to begin therapy with two-drug combinations at certain blood pressure or risk levels, (c) evidence that twodrug combinations may lead to better compliance compared with the two agents prescribed separately, (d) effects of rapidity of achieving blood pressure control on the trust in the physicianpatient relationship and its potential impact on adherence, (e) recognition of the number of agents usually required to control blood pressure tightly in large clinical trials, (f) potential advantages of accurately establishing the diagnosis of resistant hypertension with a triple-therapy combination, (g) coverage of the major underlying mechanisms of essential hypertension by the combined agents, and (h) use of agents with a proven track record to diminish untoward cardiorenal outcomes.
Moreover, it may be speculated that tripletherapy combination will also have an impact on physician inertia, which is many times fostered by the multiplicity of medications required to treat several comorbidities in elderly hypertensive patients. The reluctance that physicians may have to intensify therapy in the elderly was shown to be unfounded by the willingness and extraordinary adherence rates of the participants in the SHEP [Cooperative Research Group, 1991] and Syst-EUR [Tuomilehto et al. 1999] trials and by the low sideeffect rates in the actively treated 'superelderly' participants of HYVET [Beckett et al. 2008] . A more aggressive approach to the treatment of these patients may be facilitated if physicians can count on a simpler recourse, such as that provided by triple-therapy combination with a reasonable side-effect profile.
Finally, it is important to note that in the lipid therapy field, it has been documented that patients treated with the most potent statin (among several tested) are able to maintain controlled lipids for longer, sustained periods. This was attributed to the fact that the most powerful agent tested provided the largest margin between the NCEP recommended LDL cholesterol target and the actual achieved LDL level. In other words, treating beyond evidence-based LDL goals resulted in a higher percentage of patients maintaining evidence-based LDL goals for more prolonged periods [Andrews et al. 2001] . It can be speculated that an identical rationale is applicable to the currently unsuccessful management of hypertension. Perhaps aiming for 'normal blood pressure' with triple-therapy combination, a target not yet supported by current evidence, may increase control rates at the higher levels of blood pressure for which there is incontrovertible evidence of benefit. Sequential algorithms adding three agents (one at a time or two plus one) in patients with stages 1 and 2 hypertension have resulted in control rates up to 90% in some studies [Destro et al. 2008; Neutel et al. 2006 ]. It is conceivable that use of triple-therapy combination, extended to earlier stages in the management of essential hypertension, may improve these rates even further, not only in small clinical trials but in the general population with hypertension.
